Kauri Capital

11.8K posts

Kauri Capital banner
Kauri Capital

Kauri Capital

@KauriCapital

Undiscovered companies. Value versus price. Valuation inflection. Identifying 100 baggers.

Katılım Haziran 2015
1.9K Takip Edilen894 Takipçiler
Kauri Capital retweetledi
Kauri Capital retweetledi
alphavestcapital.com
alphavestcapital.com@alphavestcap·
Chiugray $nwbo Tuesday, May 12, 2026 12:00:52 PM Are we seeing forced buying? If so, don’t provide a release valve. The 4/30/26 “legal” Short Interest report showed an increase of 5.4M shares. But… - Price was flat. Opened and closed at $0.20 during that 10-day window. - Normal scenario, 5.4M shares of “new” short pressure over 10 days should have took NWBO’s stock price down a lot, given the volume and no catalyst event offset then. - Doesn’t make sense. marketbeat.com/stocks/OTCMKTS… The more likely scenario is Canaccord. They settled in March 6, 2026 with the SEC, FINRA, and FinCEN for $80 million, over failures in reporting suspicious activities in OTC securities between March 2018 through June 2024. A big part of the settlement is pending a satisfactory suspicious activity reporting, a lookback review (compliance issue). morningstar.com/news/dow-jones… Likely the Short Interest was a transfer from “naked FTDs” to “legal short” positions, not new shorting. That’s why there was no price increase. A "Naked Short/FTD" is potential evidence in an abusive market manipulation case or something more serious. So it is likely to satisfy compliance and to avoid other issues. The Math: It would also require them to close out any synthetic “naked” short interests. - Canaccord is smallest MM. If they have a 75M naked short position (strawman number, also part of the TBD estimated 1.5B systemic total) - They can’t move 75M to legal short all at once. - Why? Because once a short is “legal”, they have to deal with the FTD clock. - If they legalize 75M shares, they would have a finite window to maintain those borrows or buy them back. That could create a major short squeeze. - Moving in smaller 5M chunks is one way to “try” and manage it. - The squeeze would be inevitable, but if they can cover some at the beginning, at lower prices, they will try. If that is the case, as Longs we should not provide the “release valve” to the short squeeze potential, by trading shares or selling. Let price discovery force the price up. This will provide a higher “floor price” when the other MMs eventually have to cover themselves. The personality of this short squeeze is more of a correction squeeze, a price discovery for the multi-year bear raid NWBO has been manipulated by, to find a current intrinsic value for the “DCVax platform” at this pre-approval stage.
English
1
4
24
1.2K
Kauri Capital
Kauri Capital@KauriCapital·
@RIP_GOP1234 $NWBO When approval occurs at May 21–22, 2026 meeting, the company announcement will most commonly be: •3–10 business days post-meeting Approximate windows: •Earliest plausible: May 26–29 •Most probable: May 27 – June 5 •Delayed but still normal: Up to mid-June
English
1
4
23
2K
alphavestcapital.com
alphavestcapital.com@alphavestcap·
$nwbo @alphavestcap "As of April 30, 2026, Northwest Biotherapeutics (NWBO) had a short interest of 68.44 million shares sold short, representing 4.27% of the public float. This marks a 8.58% increase in short interest since the prior report. The short interest ratio (days to cover) is 7.8, meaning it would take 7.8 days of the average trading volume of 3.06 million shares to cover all short positions."
English
2
0
0
895
Kauri Capital retweetledi
alphavestcapital.com
alphavestcapital.com@alphavestcap·
$nwbo @alphavestcap acelerator Tuesday, May 12, 2026 2:35:52 PM NWBO dam beginning to show sign of leakage. Soon noise won’t be able to plug all the holes. When that happens dam will break and NWBO will be flooded with: 1. MHRA approval, followed by FDA and worldwide approval 2. Partnerships with cash infusions 3. Up listing to NYSE, others 4. Lawsuit settlements, hope for RICO charges and prison sentences for remaining MMs 5. Managements reorganization 6. Trial expansion to treat all cancers 7. New SOC for cancer 8. Public relations campaign to educate all about NWBO and potential 9. Restore hope for most cancer patients, who had none 10. NWBO will be recognized by investment banks as a strong BUY, with a solid balance sheet 11. Stock price will exceed expectations, with dividends 12. Generational wealth created for longs 13. Noise stops once their handlers stop paying them 14. LP awarded Noble Prize
English
5
6
73
1.9K
Kauri Capital retweetledi
The Dapper DO
The Dapper DO@TheDapperDO·
@brianwro @ajw02360 @METhompson72 @jaygreco194737 Welcome to the team! There are a plethora of pros here in a multitude of industries and specialties that would love to talk shop with you! As a Physician myself, I think you’re investing in a true miracle drug, but that’s just my opinion. There are many more like me! #NWBO
English
0
3
27
505
Kauri Capital retweetledi
MI Dendream
MI Dendream@MDendream·
@METhompson72 Your typical Baby BioTech(BBT) gets an MC of $4-5B with Proof of Concept pre-approval even with mid-sized rev potential . You can argue why $NWBO is 10X lower right now, but consider Your typical BBT has unreliable contract manufacturing, a small pipeline, no settlements pending
English
0
1
15
1.9K
Kauri Capital
Kauri Capital@KauriCapital·
@METhompson72 $NWBO With MHRA approval, announcements of partnerships, combo trials, new investors and other MM buying could see $7.50-$8.50 a retracement. Longer term, very large market capitalisation numbers.
English
0
0
27
809
Mark Thompson
Mark Thompson@METhompson72·
Time to put a price target on $NWBO. I am in at 20c. With MHRA approval for DC-VAX anything is possible, so this is a real thumb-suck, but $2.00 does not seem unreasonable.
Mark Thompson tweet media
English
15
9
107
7.3K
Kauri Capital retweetledi
Lou Smith 🍀
Lou Smith 🍀@smith348572·
$NWBO @MHRAgovuk and UK is a total disaster. Terrible. How come #DCVAX cell therapy is not already approved? Is someone pressuring or influencing people at @MHRAgovuk not to approve this? It has been 2.5 years since the application was submitted for approval. For a potential breakthrough cell therapy with an exceptional safety profile, the lack of transparency and leadership is becoming impossible to ignore. Maybe @Nigel_Farage should start asking why UK patients still don’t have access to this treatment. Btw, considering where the UK stands on cancer innovation and breakthrough therapies, delaying access to potentially life-extending treatments would be difficult to justify — especially for patients facing diseases with such devastating survival rates. Applicable to all solid tumors. @Siobhain_Mc @Keir_Starmer @wesstreeting @zubirahmed
Lou Smith 🍀 tweet mediaLou Smith 🍀 tweet media
English
3
10
82
1.7K
Kauri Capital retweetledi
Hoffmann
Hoffmann@hoffmann6383·
➡️Citadel is very interested in Joshua Mitts The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) The Docket: courtlistener.com/docket/6657959… In a May 1st filing in the above referenced spoofing case $NWBO asks the court for a protective order relieving Mr. Mitts from compliance with a subpoena. Mr. Mitts is $NWBO's non-testifying consulting expert and its attorney. $NWBO claims Citadel is harassing Mr. Mitts and attempting to drive up litigation costs over an improper subpoena. The subpoena asks for Mr. Mitts to turn over "troves of privileged information" which $NWBO claims is protected from disclosure. Who Is Joshua Mitts? CV: law.columbia.edu/sites/default/… Mr. Mitts and $NWBO executed a formal engagement letter on August 29, 2022. Mr. Mitts resume states, in relevant part: "...advises on the analysis of trading data in connection with high-frequency market manipulation and securities violations. He has extensive experience supporting the U.S. Department of Justice." It's no wonder why Citadel is trying to obtain Mr. Mitts communications.
English
12
30
147
15.4K
Kauri Capital retweetledi
kristen shaughnessy
kristen shaughnessy@kshaughnessy2·
$NWBO Citadel may have picked a fight with the wrong attorney “Mr. Mitts resume states, in relevant part: "...advises on the analysis of trading data in connection with high-frequency market manipulation and securities violations. He has extensive experience supporting the U.S. Department of Justice." - @hoffmann6383
Hoffmann@hoffmann6383

➡️Citadel is very interested in Joshua Mitts The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) The Docket: courtlistener.com/docket/6657959… In a May 1st filing in the above referenced spoofing case $NWBO asks the court for a protective order relieving Mr. Mitts from compliance with a subpoena. Mr. Mitts is $NWBO's non-testifying consulting expert and its attorney. $NWBO claims Citadel is harassing Mr. Mitts and attempting to drive up litigation costs over an improper subpoena. The subpoena asks for Mr. Mitts to turn over "troves of privileged information" which $NWBO claims is protected from disclosure. Who Is Joshua Mitts? CV: law.columbia.edu/sites/default/… Mr. Mitts and $NWBO executed a formal engagement letter on August 29, 2022. Mr. Mitts resume states, in relevant part: "...advises on the analysis of trading data in connection with high-frequency market manipulation and securities violations. He has extensive experience supporting the U.S. Department of Justice." It's no wonder why Citadel is trying to obtain Mr. Mitts communications.

English
4
58
187
13.6K
Kauri Capital retweetledi
PK_Fund
PK_Fund@PK_Fund·
$NWBO While we wait, seemingly forever, I wanted to put the daily volume traded into perspective so that it is clear what constitutes low volume days versus high volume days: NWBO VOLUME GUIDE, USING APPROX. 1.6B FLOAT Very Low: under 4M shares, under 0.25% of float Low: 4M to 8M shares, 0.25% to 0.50% Low/Medium: 8M to 16M shares, 0.50% to 1.00% Medium: 16M to 32M shares, 1.00% to 2.00% High: 32M to 80M shares, 2.00% to 5.00% Very High: 80M to 160M shares, 5.00% to 10.00% Extremely High: over 160M shares, over 10.00% For NWBO, I would not personally call it high volume unless it is over 30M shares, and very high volume would probably need to be over 80M shares. I think it’s important to keep this in mind as we grind through these microscopic volume days almost every day. Shorts and manipulators can easily control the price on these days, but things will become out of hand for them as soon as we get real higher volume days, which are coming!
English
0
2
11
1.1K
Kauri Capital retweetledi
Hoffmann
Hoffmann@hoffmann6383·
NWBO Spoofing Lawsuit - A Curious Defense Attorney Addition $NWBO The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) In today's filing attorney Rushmi Bhaskaran entered her appearance for Defendant G1 Execution Services LLC in $NWBO's civil spoofing lawsuit. It's interesting that G1 would bring in someone with experience on the criminal side while $NWBO's case is in civil courts. It makes you wonder what has been uncovered in discovery where Defendants felt the need to bring in this attorney at this particular stage of litigation. "Former Assistant U.S. Attorney for the Southern District of New York Rushmi Bhaskaran—who has more than 15 years of experience handling sophisticated white collar fraud and cybercrime matters—has joined Ballard Spahr’s Litigation Department and White Collar Defense and Investigations Group as partner, firm Chair Peter Michaud announced today. Rushmi is resident in the firm’s New York office." ballardspahr.com/insights/news/… "Former Southern District of New York Assistant U.S. Attorney Rushmi Bhaskaran has joined Ballard Spahr’s Litigation Department, White Collar Defense and Investigations Group, and New York office. Rushmi has investigated and prosecuted white collar criminal cases involving bank fraud, mail and wire fraud, health care fraud, securities fraud, criminal tax violations, computer crimes, money laundering, false statements, sanctions violations, and violations of the Bank Secrecy Act." bizjournals.com/newyork/potmse…
English
11
21
132
16.7K
Kauri Capital retweetledi
Hoffmann
Hoffmann@hoffmann6383·
@ChrisTruxler In my other post there is some language where NWBO accuses the other party of potentially doctoring their trading data. If true, big if, that's especially wild!
English
1
9
70
1.3K
Kauri Capital retweetledi
kristen shaughnessy
kristen shaughnessy@kshaughnessy2·
$NWBO Is Defendant G1 Execution Services LLC worried about what the trading data reveals? “..It's interesting that G1 would bring in someone with experience on the criminal side while $NWBO's case is in civil courts. It makes you wonder what has been uncovered in discovery where Defendants felt the need to bring in this attorney at this particular stage of litigation….” - @hoffmann6383
Hoffmann@hoffmann6383

NWBO Spoofing Lawsuit - A Curious Defense Attorney Addition $NWBO The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) In today's filing attorney Rushmi Bhaskaran entered her appearance for Defendant G1 Execution Services LLC in $NWBO's civil spoofing lawsuit. It's interesting that G1 would bring in someone with experience on the criminal side while $NWBO's case is in civil courts. It makes you wonder what has been uncovered in discovery where Defendants felt the need to bring in this attorney at this particular stage of litigation. "Former Assistant U.S. Attorney for the Southern District of New York Rushmi Bhaskaran—who has more than 15 years of experience handling sophisticated white collar fraud and cybercrime matters—has joined Ballard Spahr’s Litigation Department and White Collar Defense and Investigations Group as partner, firm Chair Peter Michaud announced today. Rushmi is resident in the firm’s New York office." ballardspahr.com/insights/news/… "Former Southern District of New York Assistant U.S. Attorney Rushmi Bhaskaran has joined Ballard Spahr’s Litigation Department, White Collar Defense and Investigations Group, and New York office. Rushmi has investigated and prosecuted white collar criminal cases involving bank fraud, mail and wire fraud, health care fraud, securities fraud, criminal tax violations, computer crimes, money laundering, false statements, sanctions violations, and violations of the Bank Secrecy Act." bizjournals.com/newyork/potmse…

English
8
31
127
8.7K
Kauri Capital retweetledi
kristen shaughnessy
kristen shaughnessy@kshaughnessy2·
$NWBO The six market maker defendants named in $NWBO spoofing lawsuit don’t want to hand over the trading data They are trying all sorts of delay tactics. “…Meanwhile, even though NWBO has produced 3,466 documents, no Defendant has produced more than 350 documents. Despite this, Defendants have harassed NWBO with frivolous discovery requests requiring unnecessary burden and expense to contest….” Courtesy: @hoffmann6383
Hoffmann@hoffmann6383

NWBO Spoofing Lawsuit - Joint Status Report $NWBO The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) The Docket: courtlistener.com/docket/6657959… On May 4th the parties in the above action submitted a joint status report advising the Court as to the status of discovery. Both the Defendants and NWBO submitted their own updates within the same letter. The status report contains the typical back and forth bickering. ➡️Defendants state that they are nearly complete with discovery “Defendants’ productions are complete or substantially complete.” ➡️Defendants point the finger at $NWBO for failing to agree on search terms “As of the date of this filing, NWBO has still refused to provide string-by-string hit counts for the terms Defendants proposed in February (even though NWBO confirmed it has run them).” ➡️Defendants object to $NWBO’s 150-day extension request “NWBO had agreed to produce documents responsive to several categories of Defendants’ RFPs in September 2025. Ex. A at 23. Eight months later, it has not done so—and nothing in NWBO’s request for an additional 150 days explains how more time would cure what NWBO has made no effort to accomplish.” ➡️Third-Party Discovery "On May 1, 2026, NWBO filed a letter motion seeking a protective order regarding a subpoena that Citadel Securities served on Joshua Mitts in September 2025." ➡️$NWBO points the finger at Defendants for the discovery delays “The current discovery schedule has been strained by Defendants’ repeated, prolonged, and dilatory discovery disputes.” “The Parties have continued to negotiate and work through numerous discovery issues. But discovery has been mired in disputes largely occasioned or prolonged by Defendants’ conduct.” ➡️$NWBO points at the Defendants’ meager productions to date "Meanwhile, even though NWBO has produced 3,466 documents, no Defendant has produced more than 350 documents. Despite this, Defendants have harassed NWBO with frivolous discovery requests requiring unnecessary burden and expense to contest. NWBO addresses these requests in further detail its motion to extend the case management schedule, which will be filed today." “Moreover, Defendants have limited their data productions to specific days in the relevant period, with some producing only the minutes surrounding the events alleged in the complaint. Additionally, there are inconsistencies between Defendants’ trading data, suggesting curated and incomplete productions.” ➡️My takeaway Citadel, et. al, is attempting to produce minimal documents while running out the discovery clock. $NWBO needs to pick up the pace so they get the documents that are needed. The Court's ruling on $NWBO's 150-day discovery extension along with $NWBO's protective order for Joshua Mitts will be important decisions by the Court.

English
6
50
160
10K
Kauri Capital retweetledi
Hoffmann
Hoffmann@hoffmann6383·
NWBO Spoofing Lawsuit Update $NWBO The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) The Docket: courtlistener.com/docket/6657959… Quick recap of last night's filings. Read Docket #269 update for for discovery information. Docket #266: Parties trying to clean up the dismissal and give the Court a basis to order the dismissal of Canaccord with prejudice. I believe this is all the detail we might get on the settlement terms as the terms were confidential: "They negotiated extensively and executed a confidential settlement agreement on mutually agreeable terms, including a standard requirement that Canaccord be dismissed from this action with prejudice." Docket #267/68: Joshua Mitts hired his own attorney. Docket #269: $NWBO is asking for an additional 150 days on the case management deadlines. $NWBO goes into reasons why this request is made and offers some interesting insight into the discovery and delay tactics by Defendants: ✅Search Terms "On April 17, Defendants sent hit counts for their proposed ESI searches, which use excessively narrow terms. For example, Defendant Lime Trading Corp. proposed a search protocol consisting of four terms identifying only 43 total documents, including families. Indeed, of the search terms proposed by Defendants, none captured more than 6,000 hits. By contrast, NWBO’s proposed searches resulted in 65,657 total documents. Yet, despite this already stark disparity, Defendants have continued to insist that NWBO should comply with Defendants’ even broader proposal for NWBO’s searches, which generates 170,000 hits. For example, one proposed string hit on 119,092 documents and would include irrelevant discussions of office supplies. And while NWBO has already agreed to certain revisions to its terms in the interest of moving discovery forward, Defendants refuse to do so and insist that they have “substantially completed” their document productions." ✅Citadel's Alleged Frivolous Requests "Citadel Securities LLC (“Citadel”), in particular, has relentlessly advanced frivolous discovery requests as a litigation tactic. For example, NWBO has spent months and expended endless resources negotiating Citadel’s wholly improper subpoena on its non-testifying expert and attorney, ultimately requiring NWBO to move for a protective order. See ECF 265. Moreover, after the Court denied Defendants’ second motion to compel additional baiting order calculations, ECF 255, Citadel took immediate steps to circumvent that order..." ✅Document Production "NWBO has produced 3,466 documents to date." "No Defendant has produced more than 350 documents." "...Defendants have arbitrarily and unilaterally limited their data productions to a handful of specific days in the relevant period, and sometimes even only the minutes surrounding events alleged in the complaint." "...in June 2025, NWBO served a subpoena to Financial Industry Regulatory Authority, Inc. (“FINRA”). After lengthy negotiations, FINRA made a partial production in January, with a subsequent production of archived data expected in the coming weeks." Proposed Discovery Schedule See attached Image.
Hoffmann tweet media
English
13
23
146
10.1K
Kauri Capital retweetledi
ATLnsider
ATLnsider@ATLnsider·
Annalisa Jenkins OBE direct words in yesterdays PR are a strong validation signal for $NWBO & #DCVax & Roswell Park / U of Pittsburgh IP dendritic cell vaccine platform technology, to potentially treat all or most solid tumor cancers worldwide, both operable & inoperable:
ATLnsider tweet media
English
2
18
115
9.1K
Kauri Capital retweetledi
Hoffmann
Hoffmann@hoffmann6383·
➡️A Settlement $NWBO The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) The Docket: courtlistener.com/docket/6657959… Recall, when I stated Canaccord Genuity was selling their market making division to Cantor and that could lead to a settlement as they would want to clean up before selling? See: x.com/hoffmann6383/s… Well, it happened. Just like TD settled their spoofing lawsuit prior to their Schwab sale. Here is $NWBO's recent court filing showing they have reached a settlement with Canaccord Genuity: See attached image. This should give $NWBO an infusion of cash. As a public company we should keep an eye on upcoming 10Q/10K filings to get an idea of the settlement amount.
Hoffmann tweet media
English
21
38
202
14.9K